MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration with BioNTech SE, a leader in next-generation immunotherapy. This collaboration involves an exclusive option for BioNTech to secure a global license to utilize MediLink’s innovative TMALIN antibody-drug conjugate (ADC) platform for several novel targets. A Lucrative Collaboration […]
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval for ELAHERE (mirvetuximab soravtansine-gynx), marking a major advancement for patients suffering from this challenging condition. ELAHERE is designed to treat folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or […]
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with multiple HER2-expressing advanced solid tumours. These positive outcomes mark the successful achievement of two secondary endpoints of the trial. In the primary analysis, Enhertu […]
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug conjugate (ADC) called LM-305 with AstraZeneca. LM-305 is designed to target G protein-coupled receptor, class C, group 5, member D (GPRC5D). The antibody drug conjugate consists of an anti-GPRC5D monoclonal antibody, a cytotoxic payload monomethyl auristatin E […]
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu (trastuzumab deruxtecan) for the treatment of a type of breast cancer patients. Enhertu has been approved as a monotherapy for the treatment of adult patients having unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast […]
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment of a type of metastatic breast cancer in adult patients. Enhertu is said to be a specifically engineered HER2-directed antibody drug conjugate (ADC). It is being co-developed and commercialized by […]
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric cancer. Enhertu is a HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo. According to AstraZeneca, the antibody drug conjugate delivered the desired tumor response in patients suffering […]
